“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting - Episode 1

Updates in Multiple Myeloma in the Frontline Setting

January 29, 2021
Ajai Chari, MD, Mount Sinai Hospital

,
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center

,
Saad Z. Usmani, MD, FACP, Levine Cancer Institute

,
Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Insight regarding updates in the frontline setting for patients with multiple myeloma, including quad versus triplet regimens, the use of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab, and transplant in newly diagnosed multiple myeloma.

Data from the following presentations are discussed:

  • Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. (Kaufman, ASH 2020, Abstract549)

  • Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. (Landgren, ASH 2020 Abstract 3204)

  • Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. (Perrot, ASH 2020 Abstract 143)

  • Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. (Gay, ASH 2020 Abstract141)

x